TrialBMC cancer2018

The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients.

Marilena Petrera et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.